• Pfizer is breaking its research operations into two parts: a biotech division to be led by a senior executive from Wyeth and a pharmaceutical group that will be run by a Pfizer scientist. Genius! [Bloomberg]

• Johnson & Johnson comes to the defense of biotech, claims biosimilar legislation will be harmful to patients. [Bloomberg]

• Another small-cap in trouble, Avalon Pharmaceuticals gets going concern from auditors. [BusinessWire]

• Biogen buyout rumors were swirling today as the stock’s options traded at 10x their normal volume. [TheStreet]

• Turns out that doctors write more for prescriptions that for branded drugs. Ouch. [WSJ Health Blog]

• Vasovist maker Epix Pharmaceuticals says it may need to file for bankruptcy if its recent debt restructuring fails. [Reuters UK]

• It’s Genta’s Genasense last stand – patient enrollment in worldwide phase 3 trial for advanced melanoma complete! [MarketWatch]

Related Posts